20 November 2020 - - US-based drugmaker Pfizer Inc. (NYSE: PFE) and Germany-based BioNTech SE (NASDAQ: BNTX) have submitted a request to the US Food and Drug Administration for Emergency Use Authorization of their mRNA vaccine candidate, BNT162b2 against SARS-CoV-2, which will potentially enable use of the vaccine in high-risk populations in the US by the middle to end of December 2020, the company said.

The submission is based on a vaccine efficacy rate of 95% (p